Background

Moderate to severe acute pain is a prevalent condition in the US and managing this pain, especially in the postoperative setting, remains a challenge. Existing treatments like opioids often cause side effects such as dependence, misuse, and respiratory depression, and both clinicians and patients are increasingly hesitant to use them. Cebranopadol is a first-in-class dual nociceptin/orphanin FQ peptide (NOP) and mu-opioid peptide (MOP) receptor (dual-NMR) agonist. This dual mechanism leads to potent analgesia while attenuating the negative side effects including euphoria, physical dependence, and respiratory depression of MOP agonism. These studies evaluated the safety and efficacy of cebranopadol in managing acute post-operative pain following abdominoplasty and bunionectomy.

Conclusions